MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study-Reference-Cited by-同舟云学术

MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study

Published:2018-08-07 Issue:10 Volume:84 Page:2325-2335
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Ambery Philip D.¹,Klammt Sebastian²,Posch Maximillian G.²,Petrone Marcella¹,Pu Wenji³,Rondinone Cristina³,Jermutus Lutz¹,Hirshberg Boaz³

Affiliation:

1. Cardiovascular, Renal, and Metabolism iMED; MedImmune Ltd; Cambridge UK

2. Charité Research Organisation GmbH; Berlin Germany

3. Cardiovascular, Renal, and Metabolism iMED; MedImmune Inc; Gaithersburg MD USA

Funder

MedImmune

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13688/fullpdf

Reference30 articles.

1. Type 2 diabetes: principles of pathogenesis and therapy;Stumvoll;Lancet,2005

2. How to fight obesity with antidiabetic drugs: targeting gut or kidney?;Baretić;Minerva Endocrinol,2015

3. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group;Turner;JAMA,1999

4. Continuing metformin when starting insulin in patients with type 2 diabetes: a double-blind randomized placebo-controlled trial;Douek;Diabet Med,2005

5. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial;Purnell;JAMA,1998

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article;Indian Journal of Endocrinology and Metabolism;2024-09-04

2. Pharmacokinetics and safety profiles of beinaglutide injection, a recombinant human GLP-1, in adults with overweight/obesity: results from a phase I clinical trial;Frontiers in Pharmacology;2024-08-22

3. Incretin-based therapy: a new horizon in diabetes management;Journal of Diabetes & Metabolic Disorders;2024-08-17

4. The Inferential Binding Sites of GCGR for Small Molecules Using Protein Dynamic Conformations and Crystal Structures;International Journal of Molecular Sciences;2024-08-01

5. Transforming obesity: The advancement of multi-receptor drugs;Cell;2024-07